Clinical trials: HIV, completed
HIV Infections
Camu Camu in ART-treated People Living with HIV
Persons living with HIV and receiving antiretroviral therapy (ART) remain with inflammation leading to higher risks of cardiovascular diseases, fatty liver and cancer.
- Trial name
- NCT04058392
- Testing
- Camu Camu Capsules
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
HIV/AIDS, PrEP
Pre-Exposure Prophylaxis in the Emergency Department
Despite an increasing armamentarium of behavioral and biomedical HIV prevention methods, since 2010 rates of new infection have remained around 40,000 annually.
- Trial name
- PrEPPED (NCT04429971)
- Testing
- PrEP screening program, PrEP starter pack
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
HIV
Dyadic-Based Diagnosis, Care, and Prevention for HIV Discordant Couples in Tanzania
This is a prospective observational study of couples in Kisarawe, Tanzania who will be provided an intervention that offers: (1) HIV self-testing kits and pre-test counseling provided at the household, (2) linkage to a counseling…
- Trial name
- DDCP (NCT03098693)
- Testing
- HIV Self-Testing, Immediate Access to ART for HIV infected couple members, Access to PrEP for HIV uninfected couple members
- Where
- Tanzania
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Medical University of South Carolina
HIV
Engagement to Care South Africa
This study will evaluate the efficacy of two strategies for enhancing overall preventive behaviors, retention in HIV care, and adherence to medication for HIV positive individuals in South Africa: short message service (SMS) text…
- Trial name
- ICARE (NCT02417233)
- Testing
- SMS text message, SMS text message + Peer Navigation
- Where
- 2 sites in South Africa
- Volunteers
- 756 people
- Sponsor
- University of California, San Francisco
Vaccine Adverse Reaction, Seroconversion
Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection
After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19 infection is highly needed.
- Trial name
- NCT04756271
- Testing
- SARS-Cov-2 neutralizing antibody titer
- Where
- Egypt
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Zagazig University
HIV/AIDS, Antiviral Toxicity
Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)
Increased comorbidities such as cardiovascular disease (CVD), are emerging problems in HIV infection but the mechanisms are unclear.
- Conditions
- HIV/AIDS, Antiviral Toxicity, Antiviral Drug Adverse Reaction, Mitochondrial Alteration
- Trial name
- UCLACAREMITO (NCT03251144)
- Testing
- Switch to E/C/FTC/TAF daily
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
HIV Infection, Cardiovascular Disease
The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk
It is the central hypothesis of the investigators study that HIV disease is a pro-inflammatory condition, and that years of inflammation result in premature "aging' of the immune system ("immunosenescence").
- Conditions
- HIV Infection, Cardiovascular Disease, Inflammation
- Trial name
- NCT01333644
- Where
- United States
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV
The Welcome Incoming Neighbor (WIN) Community Trial
Migration is common in rural Africa: in-migrants have higher HIV incidence and prevalence than community residents, but underutilize combined HIV prevention and care services, including voluntary medical male circumcision and…
- Trial name
- WIN (NCT03915899)
- Testing
- WIN (Welcome Incoming Neighbor)
- Where
- Uganda
- Volunteers
- 9,080 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or…
- Trial name
- NCT00120393
- Testing
- atazanavir/ritonavir +2 NRTIs (immediate Switch Group), LPV/r +2 NRTIs (Delayed/optional Switch Group)
- Where
- 14 sites in United States, Canada
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
AIN, HIV
HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)
This study evaluates vaccination with the quadrivalent HPV vaccine (Gardasil) versus placebo vaccination on prevention of high grade AIN recurrence in HIV-positive MSM (men who have sex with men) who were successfully treated for…
- Trial name
- VACCAIN-P (NCT02087384)
- Testing
- Gardasil
- Where
- 3 sites in Netherlands
- Volunteers
- 126 people
- Sponsor
- Prof. Jan Prins
HIV Infections
Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)
The researchers are involved in a phase II, randomized, two-arm study, comparing the efficacy, safety, and tolerability of open-label ritonavir (RTV)-enhanced darunavir with Truvada to a 5-drug multi-class regimen including…
- Trial name
- NCT00525733
- Testing
- darunavir 800 mg, FTC 200 mg/TDF 300mg, Maraviroc
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rockefeller University
Latent Tuberculosis Bacteriology and Histology Unknown, Latent Tuberculosis
A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)
This is a Phase I/IIa, double-blind, randomized, placebo-controlled, dose- and regimen-finding study in healthy adults with and without LTBI, who are BCG-vaccinated, HIV negative, and have no history or evidence of TB disease.
- Trial name
- NCT01865487
- Testing
- H56ug/IC31nmol
- Where
- 2 sites in South Africa
- Volunteers
- 98 people
- Sponsor
- Aeras
Health Knowledge, Attitudes, Practice, Health Risk Behaviors
Like Father Like Son
This purpose of this study is to look at the best way to offer the Like Father Like Son + Spear \& Shield program.
- Trial name
- NCT04119414
- Testing
- Spear and Shield (S&S) Program, Like Father Like Son (LFLS) Program
- Where
- Zambia
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Miami
Human Immunodeficiency Virus
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
The purpose of the study is to assess: 1 safety and tolerability of adenovirus serotype 26 (Ad26) prime and Modified Vaccinia Ankara (MVA) boost versus placebo in participants on suppressive antiretroviral therapy (ART) that was…
- Trial name
- NCT02919306
- Testing
- Ad26.Mos.HIV, MVA-Mosaic
- Where
- Thailand
- Volunteers
- 27 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
HIV Infections
Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours
Tipranavir is a drug with a high antiretroviral activity, also in presence of major mutations in the protease gene. However, its necessity of being co-administered with 400 mg of ritonavir daily, limits its efficacy for the…
- Trial name
- NCT00607958
- Testing
- tipranavir/ritonavir (dose reduction)
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Germans Trias i Pujol Hospital
HIV Infection
Strategic Timing of Antiretroviral Treatment
Objectives: To find out if the chance of developing a serious illness or of getting AIDS is less if patients start taking HIV medicines at a time when their cluster-of-differentiation-4 (CD4)+ cell count is still fairly high…
- Trial name
- START (NCT00867048)
- Testing
- All licensed antiretroviral medications
- Where
- 218 sites in United States, Argentina and 34 more
- Volunteers
- 4,688 people
- Sponsor
- University of Minnesota
HIV Infections
A Study of Ribavirin in the Treatment of Patients With AIDS and AIDS-Related Problems
To determine the maximum long-term dosage of ribavirin (RBV) that is safe and free of serious side effects in patients with AIDS or AIDS related illnesses.
- Trial name
- NCT00001015
- Testing
- Ribavirin
- Where
- 5 sites in United States
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV), Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals
The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection…
- Trial name
- MOSAICO (NCT03964415)
- Testing
- Ad26.Mos4.HIV, Clade C and Mosaic gp140 HIV bivalent vaccine
- Where
- 53 sites in United States, Argentina and 7 more
- Volunteers
- 3,900 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
HIV Infection
A Safety and Immunogenicity Trial of IHV01
This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1…
- Trial name
- FLSC-001 (NCT02756208)
- Testing
- 300 ug FLSC vaccine, 150 ug FLSC vaccine, 75 ug FLSC vaccine
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
HIV Infections, Smoking
Improving the Reach & Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV
This project will compare the effectiveness of an HIV-specific comprehensive wellness intervention designed to have broad appeal to smokers living with HIV to the effectiveness of standard care services that include referral to…
- Conditions
- HIV Infections, Smoking, Smoking Cessation
- Trial name
- WISH (NCT04505371)
- Testing
- Wellness Intervention for Smokers with HIV
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Seattle Institute for Biomedical and Clinical Research